Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-bb22e3a2d3ee768b14a39522c099f1f4",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-bb22e3a2d3ee768b14a39522c099f1f4",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-bb22e3a2d3ee768b14a39522c099f1f4",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-bb22e3a2d3ee768b14a39522c099f1f4\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-bb22e3a2d3ee768b14a39522c099f1f4</b></p><a name=\"composition-en-bb22e3a2d3ee768b14a39522c099f1f4\"> </a><a name=\"hccomposition-en-bb22e3a2d3ee768b14a39522c099f1f4\"> </a><a name=\"composition-en-bb22e3a2d3ee768b14a39522c099f1f4-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1742/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - columvi</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/23/1742/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mpbb22e3a2d3ee768b14a39522c099f1f4"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - columvi",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Columvi is and what it is used for</li><li>What you need to know before you are given Columvi</li><li>How Columvi is given</li><li>Possible side effects</li><li>How to store Columvi</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What columvi is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What columvi is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Columvi is</p><p>Columvi is a cancer medicine that contains the active substance glofitamab.</p><p>What Columvi is used for</p><p>Columvi is used to treat adults with a cancer called diffuse large B-cell lymphoma (DLBCL). It is used when the cancer:</p><ul><li>has come back (relapsed), or</li><li>did not respond to previous treatments.</li></ul><p>Diffuse large B-cell lymphoma is a cancer of a part of your immune system (the body s defences).</p><ul><li>It affects a type of white blood cell called B cells .</li><li>In DLBCL, B cells multiply in an uncontrolled manner and build up in your tissues.</li></ul><p>How Columvi works</p><ul><li>The active substance in Columvi, glofitamab, is a bispecific monoclonal antibody, a type of protein that attaches to two specific targets in the body. It attaches to a specific protein on the surface of B cells, including cancerous B cells, and also to another protein on the surface of T cells (another type of white blood cell). This activates T cells and causes them to multiply. This, in turn, results in the destruction of the B cells, including the cancerous cells.</li></ul></div>"
}
},
{
"title" : "2. What you need to know before you take columvi",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take columvi"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>You must not be given Columvi</p><ul><li>if you are allergic to glofitamab or any of the other ingredients of this medicine (listed in section 6)</li><li>if you are allergic to obinutuzumab, which is another medicine given before starting Columvi treatment (see also section 3 How Columvi is given ), or any of the other ingredients of this medicine</li></ul><p>If you are not sure if any of the above apply to you, talk to your doctor or nurse before you are given Columvi.</p><p>Warnings and precautions</p><p>Talk to your doctor before you are given Columvi if</p><ul><li>you have an infection</li><li>you have had a long-lasting infection (chronic), or an infection which keeps coming back (recurring)</li><li>you have or had any kidney, liver or heart problems</li><li>you are planning to have a vaccine in the near future</li></ul><p>If any of the above apply to you (or you are not sure), talk to your doctor before being given Columvi.</p><p>Pay attention to serious side effects.</p><p>Some side effects of Columvi are serious and can be life-threatening. These may happen any time during Columvi treatment.</p><p>Tell your doctor straight away if you experience any of the following side effects while receiving Columvi. The symptoms of each side effect are listed in section 4. * Cytokine release syndrome: an exaggerated inflammatory condition associated with medicines that stimulate T cells, characterized by fever and impairment to multiple organs in the body. Cytokine release syndrome is more likely to occur during Cycle 1 after Columvi is given (see section 3 How Columvi is given ). Close monitoring is needed. Before each infusion, you may be given medicines, which help reduce possible side effects of cytokine release syndrome.</p><ul><li>Tumour lysis syndrome: some people may get unusual levels of some salts in the blood (such as potassium and uric acid) caused by the fast breakdown of cancer cells during treatment. Your doctor or nurse will do blood tests to check for this condition. Before each infusion, you should be well-hydrated and may be given medicines that can help reduce high levels of uric acid. These may help reduce possible side effects of tumour lysis syndrome.</li><li>Tumour flare: a reaction to certain medicines that act on the immune system which is/appears similar to worsening of the cancer.</li><li>Infections: you may get signs of infection, which can vary depending on where in the body the infection is.</li></ul><p>If you have, or think you may have, any of the above symptoms tell your doctor straight away.<br/>Your doctor may:</p><ul><li>give you other medicines to reduce symptoms and prevent complications,</li><li>stop your treatment for a short time, or</li><li>stop your treatment completely.</li></ul><p>Children and adolescents</p><p>This medicine should not be given to children and adolescents below 18 years of age. This is because Columvi has not been studied in this age group. Other medicines and Columvi</p><p>Tell your doctor or nurse if you are taking, have recently taken or might start taking any other medicines. This includes medicines obtained without a prescription and herbal medicines.</p><p>Pregnancy and contraception</p><ul><li>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</li><li>You should not be given Columvi if you are pregnant. This is because it is possible that Columvi could harm your unborn baby.</li><li>If you could become pregnant, you must use effective contraception while you are being treated with Columvi and for 2 months after the last dose.</li><li>If you become pregnant while you are being treated with Columvi tell your doctor immediately.</li></ul><p>Breast-feeding</p><p>Do not breast-feed while receiving Columvi and for at least 2 months after the last dose. This is because it is not known if this medicine can pass into breast milk and harm your baby.</p><p>Driving and using machines</p><p>Columvi has minor influence on your ability to drive, cycle or use any tools or machines.</p><p>If you feel any symptoms that may affect your ability to drive, including symptoms of cytokine release syndrome (such as fever, fast heartbeat, feeling dizzy or lightheaded, chills or shortness of breath) do not drive, cycle or use any tools or machines until you feel better. See section 4 for more information about side effects.</p></div>"
}
},
{
"title" : "3. How to take columvi",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take columvi"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>You will be given Columvi under the supervision of a doctor experienced in cancer treatment, in a hospital or clinic.</p><p>Medicines given before Columvi treatment</p><ul><li>Seven days before starting Columvi treatment, you will be given another medicine, obinutuzumab, to reduce the number of B cells in your blood.</li><li>30 to 60 minutes before you are given Columvi, you may be given other medicines (pre-medication) to help reduce reactions associated with cytokine release syndrome. These medicines may include:</li></ul><ul><li>A corticosteroid such as dexamethasone</li><li>A fever-reducing medicine such as paracetamol</li><li>An antihistamine such as diphenhydramine</li></ul><p>How much and how often you will receive Columvi</p><p>You may be given up to 12 treatment cycles of Columvi. Each cycle lasts 21 days. During the first two cycles, your doctor will begin Columvi treatment with a low dose and will gradually increase it to the full dose.</p><p>A typical schedule is shown below.</p><p>Cycle 1: This will include a pre-treatment and 2 low doses of Columvi during the 21 days:</p><ul><li>Day 1 Pre-treatment with obinutuzumab</li><li>Day 8 2.5 mg starting dose of Columvi</li><li>Day 15 10 mg intermediate dose of Columvi</li></ul><p>Cycle 2 to Cycle 12: This will be just one dose in the 21 days:</p><ul><li>Day 1 30 mg full dose of Columvi</li></ul><p>How Columvi is given and monitoring</p><p>Columvi is given as a drip into a vein (an intravenous infusion). Your doctor will adjust the time required for infusion depending on how you respond to treatment.</p><ul><li>Your first infusion will be given over 4 hours. Your doctor will monitor you carefully during the first infusion and for 10 hours after completion of infusion. This is to watch for any signs or symptoms of cytokine release syndrome.</li><li>For following infusions, your doctor may require to monitor you after completion of infusion. This will be necessary if you have had moderate or severe cytokine release syndrome with your previous dose.</li><li>If you do not have any cytokine release syndrome after 3 doses, your doctor may give the following infusions over 2 hours.</li></ul><p>If you miss a dose of Columvi</p><p>If you miss an appointment, make another one straight away. For the treatment to be fully effective, it is very important not to miss a dose.</p><p>Before stopping Columvi treatment</p><p>Speak with your doctor before stopping treatment. This is because stopping treatment may make your condition worse.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects</p><p>Tell your doctor straight away if you get any of the serious side effects listed below you may need urgent medical treatment.</p><ul><li>Cytokine release syndrome (very common): symptoms may include, but are not limited to, fever, fast heartbeat, feeling dizzy or lightheaded, nausea, headache, rash, confusion, chills, shortness of breath</li><li>Infections (very common): symptoms may include, but are not limited to, fever, chills, difficulty breathing, burning pain when passing urine</li><li>Tumour flare (very common): symptoms may include, but are not limited to, tender swollen lymph nodes, chest pain, inability to breathe easily, pain at the site of the tumour</li><li>Tumour lysis syndrome (common): symptoms may include, but are not limited to, weakness, shortness of breath, feeling confused, irregular heartbeat, muscle cramps</li></ul><p>Other side effects</p><p>Tell your doctor or nurse straight away if you notice any of the following side effects or if they get worse:</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>lowered levels, as measured in blood tests, of:</li></ul><ul><li>neutrophils (a type of white blood cell; neutropenia), which may cause fever or any symptoms of an infection</li><li>red blood cells (anaemia), which may cause tiredness, feeling unwell and pale skin</li><li>platelets (a type of blood cell; thrombocytopenia), which may cause bruising or bleeding</li></ul><ul><li>fever</li><li>low levels, as measured in blood tests, of phosphate, magnesium, calcium or potassium</li><li>rash</li><li>constipation</li><li>diarrhoea</li><li>feeling sick (nausea)</li><li>viral infections, such as lung infection, shingles</li><li>headache</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>low sodium levels, as measured in blood tests, which may cause tiredness, muscle twitching or cramps</li><li>increased levels, as measured in blood tests, of liver enzymes and bilirubin (yellow substance in blood), which may cause yellowing of skin or eyes, and dark urine</li><li>bacterial infections, such as urinary tract infection, infection in or around the stomach</li><li>fungal infection</li><li>nose and throat infections (upper respiratory tract infections)</li><li>infections of the lungs such as bronchitis or pneumonia (lower respiratory tract infections), which may cause fever, cough, and difficulty breathing</li><li>blood poisoning (sepsis), which may cause fever, chills and confusion</li><li>low levels, as measured in blood tests, of lymphocytes (a type of white blood cell; lymphopenia)</li><li>fever with low levels of neutrophils (febrile neutropenia)</li><li>vomiting</li><li>bleeding in the stomach or gut (gastrointestinal haemorrhage), which may cause black stools or blood in vomit</li><li>confusion</li><li>trembling</li><li>sleepiness</li></ul><p>Uncommon (may affect less than 1 in 100 people)</p><ul><li>swelling of the spinal cord (myelitis), which may cause muscle weakness or numbness</li></ul><p>If you notice any of the side effects above or if they get worse, tell your doctor straight away.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store columvi",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store columvi"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Your doctor, pharmacist or nurse is responsible for storing this medicine and disposing of any unused product correctly. The following information is intended for healthcare professionals.</p><ul><li>Keep this medicine out of the sight and reach of children.</li><li>Do not use this medicine after the expiry date, which is stated on the carton and the vial label after EXP. The expiry date refers to the last day of that month.</li><li>Store in a refrigerator (2 C - 8 C).</li><li>Do not freeze.</li><li>Keep the vial in the outer carton in order to protect from light.</li><li>Do not use this medicine if it appears cloudy, discoloured or contains particles.</li></ul><p>Any unused medicine or waste material should be disposed of in accordance with local requirements.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Columvi contains</p><ul><li>The active substance is glofitamab.</li><li>Columvi 2.5 mg: Each vial contains 2.5 milligrams of glofitamab (in 2.5 mL concentrate) at a concentration of 1 mg/mL</li><li>Columvi 10 mg: Each vial contains 10 milligrams of glofitamab (in 10 mL concentrate) at a concentration of 1 mg/mL</li><li>The other ingredients are: L-histidine, L-histidine hydrochloride monohydrate, L-methionine, sucrose, polysorbate 20 (E432) and water for injections.</li></ul><p>What Columvi looks like and contents of the pack</p><p>Columvi concentrate for solution for infusion (sterile concentrate) is a colourless, clear solution provided in a glass vial.</p><p>Each pack of Columvi contains one vial.</p><p>Marketing Authorisation Holder</p><p>Roche Registration GmbH Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany</p><p>Manufacturer</p><p>Roche Pharma AG Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien N.V. Roche S.A.<br/>T l/Tel: +32 (0) 2 525 82 Lietuva UAB Roche Lietuva<br/>Tel: +370 5 2546</p><p>: +359 2 818 44 Luxembourg/Luxemburg (Voir/siehe Belgique/Belgien) esk republika Roche s. r. o.<br/>Tel: +420 - 2 20382Magyarorsz g Roche (Magyarorsz g) Kft.<br/>Tel: +36 - 1 279 4Danmark Roche Pharmaceuticals A/S Tlf: +45 - 36 39 Malta (See Ireland)</p><p>Deutschland Roche Pharma AG<br/>Tel: +49 (0) 7624 Nederland Roche Nederland B.V.<br/>Tel: +31 (0) 348 438Eesti Roche Eesti O<br/>Tel: + 372 - 6 177 Norge Roche Norge AS<br/>Tlf: +47 - 22 78 90<br/>Roche (Hellas) A.E.<br/>: +30 210 61 66 sterreich Roche Austria GmbH<br/>Tel: +43 (0) 1 27Espa a Roche Farma S.A.<br/>Tel: +34 - 91 324 81 Polska Roche Polska Sp.z o.o.<br/>Tel: +48 - 22 345 18 France Roche<br/>T l: +33 (0) 1 47 61 40 Portugal Roche Farmac utica Qu mica, Lda<br/>Tel: +351 - 21 425 70 Hrvatska Roche d.o.o.<br/>Tel: +385 1 4722 Rom nia Roche Rom nia S.R.L.<br/>Tel: +40 21 206 47 Ireland Roche Products (Ireland) Ltd.<br/>Tel: +353 (0) 1 469 0Slovenija Roche farmacevtska dru ba d.o.o.<br/>Tel: +386 - 1 360 26 sland Roche Pharmaceuticals A/S<br/>c/o Icepharma hf<br/>S mi: +354 540 8Slovensk republika Roche Slovensko, s.r.o.<br/>Tel: +421 - 2 52638Italia Roche S.p.A.<br/>Tel: +39 - 039 2Suomi/Finland Roche Oy<br/>Puh/Tel: +358 (0) 10 554<br/>. . & .<br/>: +357 - 22 76 62 Sverige Roche AB<br/>Tel: +46 (0) 8 726 1Latvija Roche Latvija SIA<br/>Tel: +371 - 6 7039United Kingdom (Northern Ireland) Roche Products (Ireland) Ltd.<br/>Tel: +44 (0) 1707 366This leaflet was last revised in</p><p>This medicine has been given conditional approval . This means that there is more evidence to come about this medicine. The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mpbb22e3a2d3ee768b14a39522c099f1f4",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mpbb22e3a2d3ee768b14a39522c099f1f4",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mpbb22e3a2d3ee768b14a39522c099f1f4\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mpbb22e3a2d3ee768b14a39522c099f1f4</b></p><a name=\"mpbb22e3a2d3ee768b14a39522c099f1f4\"> </a><a name=\"hcmpbb22e3a2d3ee768b14a39522c099f1f4\"> </a><a name=\"mpbb22e3a2d3ee768b14a39522c099f1f4-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1742/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Columvi 2.5 mg concentrate for solution for infusion</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/23/1742/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Columvi 2.5 mg concentrate for solution for infusion",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
